Loading stock data…
$0.18-0.01 (-3.35%)
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia.
VolitionRx Limited in the Healthcare sector is trading at $0.18 with a market capitalization of $6M. Wall Street consensus targets $13.62 (5 analysts), implying a +7531.4% move over the next 12 months. The stock is currently near its 52-week low of $0.18, remaining 92.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $398,657↓ | $985,076↑ | $447,034↓ | $627,277↑ | $406,688 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.20M↑ | -$5.23M↓ | -$4.73M↑ | -$4.87M↑ | -$6.22M |
| Net Income | -$7.33M↓ | -$6.66M↓ | -$6.27M↓ | -$5.38M↑ | -$6.28M |
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening...